{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:33Z","timestamp":1791272373322,"version":"4.1.0"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/151145\/2021"],"award-info":[{"award-number":["SFRH\/BD\/151145\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Prostate cancer (PCa) remains one of the most commonly diagnosed malignancies and a leading cause of cancer-related morbidity and mortality among men worldwide. Despite considerable progress in diagnostic and therapeutic modalities, conventional approaches often fall short in capturing disease heterogeneity and managing advanced or treatment-resistant cases. Over the past years, molecular imaging and targeted radionuclide therapy within a theranostic framework have emerged as powerful tools to potentially overcome these limitations. In this context, copper radioisotopes\u2014particularly copper-61 (T\n                      <jats:sub>1\/2<\/jats:sub>\n                      = 3.33\u00a0h; 61% \u03b2\n                      <jats:sup>+<\/jats:sup>\n                      ), copper-64 (T\n                      <jats:sub>1\/2<\/jats:sub>\n                      = 12.7\u00a0h; 17% \u03b2\n                      <jats:sup>+<\/jats:sup>\n                      , 39% \u03b2\n                      <jats:sup>\u2013<\/jats:sup>\n                      ), and copper-67 (T\n                      <jats:sub>1\/2<\/jats:sub>\n                      = 2.58 d; 100% \u03b2\n                      <jats:sup>\u2013<\/jats:sup>\n                      )\u2014have garnered considerable attention due to their favorable half-lives, straightforward coordination chemistry, and optimal physical decay properties for both imaging and therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This review comprehensively examines the progress and prospects of copper-based radiopharmaceuticals for PCa theranostics, with particular emphasis on agents targeting prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR), the two most extensively studied and clinically relevant molecular targets in this setting. Alternative markers are also discussed as promising avenues to tackle disease heterogeneity and expand the clinical applicability of these conjugates. By consolidating preclinical and clinical evidence, we aim to identify current challenges and opportunities in the development of copper-based radiopharmaceuticals, and contribute to a paradigm shift toward the widespread clinical adoption of these novel radiopharmaceutical platforms for improved patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Copper-based radiopharmaceuticals represent a promising class of agents with the potential to refine PCa management. As research advances, these compounds are poised to enhance diagnostic precision and therapeutic efficacy, paving the way for more personalized strategies and favorable clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01325-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:52:25Z","timestamp":1763463145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-2841","authenticated-orcid":false,"given":"Diana","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1924-178X","authenticated-orcid":false,"given":"Alexandra I.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-0522","authenticated-orcid":false,"given":"Jo\u00e3o N.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-4129","authenticated-orcid":false,"given":"C\u00e9lia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-854X","authenticated-orcid":false,"given":"Antero","family":"Abrunhosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"3","key":"1325_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1325_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.biotechadv.2016.11.009","volume":"35","author":"S Sharma","year":"2017","unstructured":"Sharma S, Zapatero-Rodr\u00edguez J, O\u2019Kennedy R. Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnol Adv. 2017;35(2):135\u201349.","journal-title":"Biotechnol Adv"},{"issue":"6","key":"1325_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/diseases13060167","volume":"13","author":"Z Dushimova","year":"2025","unstructured":"Dushimova Z, Iztleuov Y, Chingayeva G, Shepetov A, Mustapayeva N, Shatkovskaya O, et al. Overdiagnosis and overtreatment in prostate cancer. Diseases. 2025;13(6):167. https:\/\/doi.org\/10.3390\/diseases13060167","journal-title":"Diseases"},{"key":"1325_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132137","volume":"17","author":"E Kania","year":"2025","unstructured":"Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J. Advances and challenges in prostate cancer diagnosis: a comprehensive review. Cancers (Basel). 2025;17:13.","journal-title":"Cancers (Basel)"},{"key":"1325_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215360","volume":"13","author":"R Manafi-Farid","year":"2021","unstructured":"Manafi-Farid R, Ranjbar S, Araghi ZJ, Pilz J, Schweighofer-Zwink G, Pirich C, et al. Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends. Cancers (Basel). 2021;13:21.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1325_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","volume":"27","author":"L Wang","year":"2025","unstructured":"Wang L, Wang L, Wang X, Wu D. The evolving role of PSMA-PET\/CT in prostate cancer management: an umbrella review of diagnostic Restaging, therapeutic Redirection, and survival impact. Curr Oncol Rep. 2025;27(6):774\u201387.","journal-title":"Curr Oncol Rep"},{"key":"1325_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"1325_CR8","doi-asserted-by":"crossref","unstructured":"Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P et al. Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 2023;12(80).","DOI":"10.1186\/s40164-023-00444-9"},{"issue":"12","key":"1325_CR9","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793\u20139.","journal-title":"J Nucl Med"},{"issue":"12","key":"1325_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10276","key":"1325_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"2","key":"1325_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1325_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.drudis.2018.04.002","volume":"23","author":"A Boschi","year":"2018","unstructured":"Boschi A, Martini P, Janevik-Ivanovska E, Duatti A. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. Drug Discov Today. 2018;23(8):1489\u2013501.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1325_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41181-019-0088-x","volume":"5","author":"SJC do Carmo","year":"2020","unstructured":"do Carmo SJC, Scott PJH, Alves F. Production of radiometals in liquid targets. EJNMMI Radiopharm Chem. 2020;5(1):2. https:\/\/doi.org\/10.1186\/s41181-019-0088-x","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1325_CR15","doi-asserted-by":"publisher","unstructured":"Mou L, Martini P, Pupillo G, Cieszykowska I, Cutler CS, Miko\u0142ajczak R. 67Cu production capabilities: a mini review. Molecules. 2022;27(5):1501. https:\/\/doi.org\/10.3390\/molecules27051501","DOI":"10.3390\/molecules27051501"},{"issue":"3","key":"1325_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/15422119.2023.2270469","volume":"53","author":"AI Fonseca","year":"2024","unstructured":"Fonseca AI, Do Carmo SJC, Hrynchak I, Alves V, Alves F, Abrunhosa AJ. Purification of copper radioisotopes for medical applications: chromatographic methods and challenges. Sep Purif Rev. 2024;53(3):289\u2013310.","journal-title":"Sep Purif Rev"},{"issue":"4","key":"1325_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0969-8051(98)00113-9","volume":"26","author":"DW Mccarthy","year":"1999","unstructured":"Mccarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, et al. High purity production and potential applications of Copper-60 and Copper-61. Nucl Med Biol. 1999;26(4):351\u20138.","journal-title":"Nucl Med Biol"},{"issue":"3","key":"1325_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0969-8043(93)90172-7","volume":"44","author":"F Szelecsfinyi","year":"1993","unstructured":"Szelecsfinyi F, Blessing G, Qaiw SM. Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl Radiat Isot. 1993;44(3):575\u201380.","journal-title":"Appl Radiat Isot"},{"key":"1325_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1063\/1.4773947","volume":"1509","author":"AH Asad","year":"2012","unstructured":"Asad AH, V. Smith S, Chan S, Jeffery CM, Morandeau L, Price RI. Cyclotron production of 61Cu using natural Zn & enriched 64Zn targets. AIP Conf Proc. 2012;1509:91\u20135.","journal-title":"AIP Conf Proc"},{"issue":"42","key":"1325_CR20","doi-asserted-by":"publisher","first-page":"14556","DOI":"10.1039\/C7DT01836C","volume":"46","author":"SJC Do Carmo","year":"2017","unstructured":"Do Carmo SJC, Alves VHP, Alves F, Abrunhosa AJ. Fast and cost-effective cyclotron production of 61Cu using a NatZn liquid target: an opportunity for radiopharmaceutical production and R&d. Dalton Trans. 2017;46(42):14556\u201360.","journal-title":"Dalton Trans"},{"key":"1325_CR21","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.apradiso.2022.110466","volume":"190","author":"G Dellepiane","year":"2022","unstructured":"Dellepiane G, Casolaro P, Mateu I, Scampoli P, Voeten N, Braccini S. Cross-section measurement for an optimized 61Cu production at an 18 MeV medical cyclotron from natural Zn and enriched 64Zn solid targets. Appl Radiat Isot. 2022;190:110466. https:\/\/doi.org\/10.1016\/j.apradiso.2022.110466","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"1325_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/ph15060723","volume":"15","author":"AI Fonseca","year":"2022","unstructured":"Fonseca AI, Alves VH, Do Carmo SJC, Silva M, Hrynchak I, Alves F, et al. Production of GMP-compliant clinical amounts of Copper-61 radiopharmaceuticals from liquid targets. Pharmaceuticals. 2022;15(6):723. https:\/\/doi.org\/10.3390\/ph15060723","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1325_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41181-020-00108-7","volume":"5","author":"J Svedjehed","year":"2020","unstructured":"Svedjehed J, Kutyreff CJ, Engle JW, Gagnon K. Automated, cassette-based isolation and formulation of high-purity [61Cu]CuCl2 from solid Ni targets. EJNMMI Radiopharm Chem. 2020;5(1):21. https:\/\/doi.org\/10.1186\/s41181-020-00108-7","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1325_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0020-708X(78)90094-7","volume":"29","author":"H Muramatsu","year":"1978","unstructured":"Muramatsu H, Shirai E, Nakahara H, Murakami Y. Alpha particle bombardment of natural nickel target for the production of 61Cu. Int J Appl Radiat Isot. 1978;29:611\u20134.","journal-title":"Int J Appl Radiat Isot"},{"key":"1325_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1524\/ract.92.4.209.35593","volume":"92","author":"T Fukumura","year":"2004","unstructured":"Fukumura T, Okada K, Szelecs\u00e9nyi F, Kov\u00e1cs Z, Suzuki K. Practical production of 61Cu using natural Co target and its simple purification with a chelating resin for 61Cu-ATSM. Radiochim Acta. 2004;92:209\u201314.","journal-title":"Radiochim Acta"},{"issue":"10","key":"1325_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.apradiso.2007.05.012","volume":"65","author":"MA Avila-Rodriguez","year":"2007","unstructured":"Avila-Rodriguez MA, Nye JA, Nickles RJ. Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Appl Radiat Isot. 2007;65(10):1115\u201320.","journal-title":"Appl Radiat Isot"},{"issue":"17","key":"1325_CR27","doi-asserted-by":"publisher","first-page":"1740013","DOI":"10.1142\/S0217732317400132","volume":"32","author":"F Alves","year":"2017","unstructured":"Alves F, Alves VHP, Do Carmo SJC, Neves ACB, Silva M, Abrunhosa AJ. Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets. Mod Phys Lett A. 2017;32(17):1740013. https:\/\/doi.org\/10.1142\/S0217732317400132","journal-title":"Mod Phys Lett A"},{"issue":"3","key":"1325_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nimb.2005.05.057","volume":"240","author":"F Szelecs\u00e9nyi","year":"2005","unstructured":"Szelecs\u00e9nyi F, Steyn GF, Kov\u00e1cs Z, Vermeulen C, Van Der Meulen NP, Dolley SG, et al. Investigation of the 66Zn(p,2pn)64Cu and 68Zn(p,x)64Cu nuclear processes up to 100 MeV: production of 64Cu. Nucl Instrum Methods Phys Res B. 2005;240(3):625\u201337.","journal-title":"Nucl Instrum Methods Phys Res B"},{"issue":"6","key":"1325_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1515\/ract-2013-2145","volume":"102","author":"F Szelecs\u00e9nyi","year":"2014","unstructured":"Szelecs\u00e9nyi F, Kov\u00e1cs Z, Nagatsu K, Zhang MR, Suzuki K. Excitation function of (p,\u03b1) nuclear reaction on enriched 67Zn: possibility of production of 64Cu at low energy cyclotron. Radiochim Acta. 2014;102(6):465\u201372.","journal-title":"Radiochim Acta"},{"issue":"1","key":"1325_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1023\/A:1024703022762","volume":"257","author":"ML Bonardi","year":"2003","unstructured":"Bonardi ML, Groppi F, Birattari C, Gini L, Mainardi C, Ghioni A, et al. Thin-target excitation functions and optimization of simultaneous production of NCA copper-64 and gallium-66,67 by deuteron induced nuclear reactions on a natural zinc target. J Radioanal Nucl Chem. 2003;257(1):229\u201341.","journal-title":"J Radioanal Nucl Chem"},{"issue":"2","key":"1325_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1524\/ract.2007.95.2.75","volume":"95","author":"J Kozempel","year":"2007","unstructured":"Kozempel J, Abbas K, Simonelli F, Zampese M, Holzwarth U, Gibson N, et al. A novel method for n.c.a. 64Cu production by the 64Zn(d,2p)64Cu reaction and dual ion-exchange column chromatography. Radiochim Acta. 2007;95(2):75\u201380.","journal-title":"Radiochim Acta"},{"issue":"2","key":"1325_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1524\/ract.2006.94.2.63","volume":"94","author":"IA Abbasi","year":"2006","unstructured":"Abbasi IA, Zaidi JH, Arif M, Subhani MS. Measurement of fission neutron spectrum averaged cross sections of some threshold reactions on zinc: small-scale production of no-carrier-added 64Cu in a nuclear reactor. Radiochim Acta. 2006;94(2):63\u20137.","journal-title":"Radiochim Acta"},{"issue":"2","key":"1325_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10967-010-0519-3","volume":"284","author":"TH Bokhari","year":"2010","unstructured":"Bokhari TH, Mushtaq A, Khan IU. Production of low and high specific activity 64Cu in a reactor. J Radioanal Nucl Chem. 2010;284(2):265\u201371.","journal-title":"J Radioanal Nucl Chem"},{"issue":"1","key":"1325_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10967-015-4032-6","volume":"305","author":"AM Johnsen","year":"2015","unstructured":"Johnsen AM, Heidrich BJ, Durrant CB, Bascom AJ, \u00dcnl\u00fc K. Reactor production of 64Cu and 67Cu using enriched zinc target material. J Radioanal Nucl Chem. 2015;305(1):61\u201371.","journal-title":"J Radioanal Nucl Chem"},{"issue":"111","key":"1325_CR35","doi-asserted-by":"publisher","first-page":"91723","DOI":"10.1039\/C5RA17266G","volume":"5","author":"R Chakravarty","year":"2015","unstructured":"Chakravarty R, Chakraborty S, Vimalnath KV, Shetty P, Sarma HD, Hassan PA, et al. 64CuCl2 produced by direct neutron activation route as a cost-effective probe for cancer imaging: the journey has begun. RSC Adv. 2015;5(111):91723\u201333.","journal-title":"RSC Adv"},{"key":"1325_CR36","unstructured":"RadioMedix, Curium Announce FDA. Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S. [Internet]. 2020 [cited 2025 Jun 22]. Available from: https:\/\/www.curiumpharma.com\/2020\/09\/08\/radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-u-s\/"},{"issue":"2","key":"1325_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10967-007-7144-9","volume":"277","author":"T Katabuchi","year":"2008","unstructured":"Katabuchi T, Watanabe S, Ishioka NS, Iida Y, Hanaoka H, Endo K, et al. Production of 67Cu via the 68Zn(p,2p)67Cu reaction and recovery of 68Zn target. J Radioanal Nucl Chem. 2008;277(2):467\u201370.","journal-title":"J Radioanal Nucl Chem"},{"issue":"11","key":"1325_CR38","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.nimb.2009.03.097","volume":"267","author":"F Szelecs\u00e9nyi","year":"2009","unstructured":"Szelecs\u00e9nyi F, Steyn GF, Dolley SG, Kov\u00e1cs Z, Vermeulen C, van der Walt TN. Investigation of the 68Zn(p,2p)67Cu nuclear reaction: new measurements up to 40 MeV and compilation up to 100 MeV. Nucl Instrum Methods Phys Res B. 2009;267(11):1877\u201381.","journal-title":"Nucl Instrum Methods Phys Res B"},{"issue":"3","key":"1325_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.apradiso.2011.10.007","volume":"70","author":"DG Medvedev","year":"2012","unstructured":"Medvedev DG, Mausner LF, Meinken GE, Kurczak SO, Schnakenberg H, Dodge CJ, et al. Development of a large scale production of 67Cu from 68Zn at the high energy proton accelerator: closing the 68Zn cycle. Appl Radiat Isot. 2012;70(3):423\u20139.","journal-title":"Appl Radiat Isot"},{"issue":"2","key":"1325_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1524\/ract.1999.84.2.107","volume":"84","author":"S Kastleiner","year":"1999","unstructured":"Kastleiner S, Coenen HH, Qaim SM. Possibility of production of 67Cu at a Small-Sized cyclotron via the (p,a)-Reaction on enriched 70Zn. Radiochim Acta. 1999;84(2):107\u201310.","journal-title":"Radiochim Acta"},{"issue":"7","key":"1325_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1524\/ract.2012.1939","volume":"100","author":"J Kozempel","year":"2012","unstructured":"Kozempel J, Abbas K, Simonelli F, Bulgheroni A, Holzwarth U, Gibson N. Preparation of 67Cu via deuteron irradiation of 70Zn. Radiochim Acta. 2012;100(7):419\u201324.","journal-title":"Radiochim Acta"},{"issue":"5","key":"1325_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/18811248.1964.9732104","volume":"1","author":"E Shikata","year":"1964","unstructured":"Shikata E. Research of radioisotope production with fast neutrons, (VI). J Nucl Sci Technol. 1964;1(5):177\u201380.","journal-title":"J Nucl Sci Technol"},{"key":"1325_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0020-708X(69)90149-5","volume":"20","author":"HA O\u2019brien","year":"1969","unstructured":"O\u2019brien HA. The preparation of 67Cu from 67Zn in a nuclear reactor. Int J Appl Radiat Isot. 1969;20:121\u20134.","journal-title":"Int J Appl Radiat Isot"},{"issue":"1","key":"1325_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0883-2889(86)90192-9","volume":"37","author":"S Mirzadeh","year":"1986","unstructured":"Mirzadeh S, Mausner LF, Srivastava SC. Production of no-carrier added 67Cu. Int J Rad Appl Instrum A. 1986;37(1):29\u201336.","journal-title":"Int J Rad Appl Instrum A"},{"key":"1325_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1524\/ract.92.3.183.30489","volume":"92","author":"I Spahn","year":"2004","unstructured":"Spahn I, Coenen HH, Qaim SM. Enhanced production possibility of the therapeutic radionuclides 64Cu, 67Cu and 89Sr via (n,p) reactions induced by fast spectral neutrons. Radiochim Acta. 2004;92:183\u20136.","journal-title":"Radiochim Acta"},{"issue":"3","key":"1325_CR46","doi-asserted-by":"publisher","first-page":"034201","DOI":"10.7566\/JPSJ.82.034201","volume":"82","author":"T Kin","year":"2013","unstructured":"Kin T, Nagai Y, Iwamoto N, Minato F, Iwamoto O, Hatsukawa Y, et al. New production routes for medical isotopes 64Cu and 67Cu using accelerator neutrons. J Phys Soc Jpn. 2013;82(3):034201. https:\/\/doi.org\/10.7566\/JPSJ.82.034201","journal-title":"J Phys Soc Jpn"},{"issue":"7","key":"1325_CR47","doi-asserted-by":"publisher","first-page":"073201","DOI":"10.7566\/JPSJ.83.073201","volume":"83","author":"N Sato","year":"2014","unstructured":"Sato N, Tsukada K, Watanabe S, Ishioka NS, Kawabata M, Saeki H, et al. First measurement of the radionuclide purity of the therapeutic isotope 67Cu produced by 68Zn(n,x) reaction using natC(d,n) neutrons. J Phys Soc Jpn. 2014;83(7):073201. https:\/\/doi.org\/10.7566\/JPSJ.83.073201","journal-title":"J Phys Soc Jpn"},{"issue":"2","key":"1325_CR48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10967-014-3488-0","volume":"303","author":"M Kawabata","year":"2015","unstructured":"Kawabata M, Hashimoto K, Saeki H, Sato N, Motoishi S, Takakura K, et al. Production and separation of 64Cu and 67Cu using 14\u00a0MeV neutrons. J Radioanal Nucl Chem. 2015;303(2):1205\u20139.","journal-title":"J Radioanal Nucl Chem"},{"issue":"7","key":"1325_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1515\/ract-2017-2847","volume":"106","author":"A Gopalakrishna","year":"2018","unstructured":"Gopalakrishna A, Suryanarayana SV, Naik H, DIxit TS, Nayak BK, Kumar A, et al. Production, separation and supply prospects of 67Cu with the development of fast neutron sources and photonuclear technology. Radiochim Acta. 2018;106(7):549\u201357.","journal-title":"Radiochim Acta"},{"issue":"3","key":"1325_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10967-021-07987-3","volume":"330","author":"M Kawabata","year":"2021","unstructured":"Kawabata M, Motoishi S, Ohta A, Motomura A, Saeki H, Tsukada K, et al. Large scale production of 64Cu and 67Cu via the 64Zn(n,p)64Cu and 68Zn(n,np\/d)67Cu reactions using accelerator neutrons. J Radioanal Nucl Chem. 2021;330(3):913\u201322.","journal-title":"J Radioanal Nucl Chem"},{"key":"1325_CR51","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/0020-708X(70)90121-3","volume":"21","author":"N Marceau","year":"1970","unstructured":"Marceau N, Kruck TPA, Mcconnell DB, Aspin N. The production of copper 67 from natural zinc using a linear accelerator. Int J Appl Radiat Isot. 1970;21:667\u20139.","journal-title":"Int J Appl Radiat Isot"},{"issue":"supplement 2","key":"1325_CR52","first-page":"1107","volume":"57","author":"J Stoner","year":"2016","unstructured":"Stoner J, Gardner T, Gardner T. A comparison of DOTA and DiamSar chelates of high specific activity eLINAC produced 67Cu. J Nucl Med. 2016;57(supplement 2):1107.","journal-title":"J Nucl Med"},{"key":"1325_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.nimb.2021.04.016","volume":"498","author":"GH Hovhannisyan","year":"2021","unstructured":"Hovhannisyan GH, Bakhshiyan TM, Dallakyan RK. Photonuclear production of the medical isotope 67Cu. Nucl Instrum Methods Phys Res B. 2021;498:48\u201351.","journal-title":"Nucl Instrum Methods Phys Res B"},{"issue":"3","key":"1325_CR54","doi-asserted-by":"publisher","first-page":"035002","DOI":"10.1088\/1361-6560\/abca52","volume":"66","author":"MJ Merrick","year":"2021","unstructured":"Merrick MJ, Rotsch DA, Tiwari A, Nolen J, Brossard T, Song J, et al. Imaging and dosimetric characteristics of 67Cu. Phys Med Biol. 2021;66(3):035002. https:\/\/doi.org\/10.1088\/1361-6560\/abca52","journal-title":"Phys Med Biol"},{"key":"1325_CR55","unstructured":"Conry RR, Copper. Inorganic & coordination chemistry. Encyclopedia of inorganic chemistry. John Wiley & Sons, Ltd.; 2006."},{"issue":"5","key":"1325_CR56","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/cr900325h","volume":"110","author":"TJ Wadas","year":"2010","unstructured":"Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858\u2013902.","journal-title":"Chem Rev"},{"issue":"1","key":"1325_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/138161207779313768","volume":"13","author":"TJ Wadas","year":"2007","unstructured":"Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13(1):3\u201316.","journal-title":"Curr Pharm Des"},{"key":"1325_CR58","doi-asserted-by":"crossref","unstructured":"Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Transactions [Internet]. 2011 May 31 [cited 2025 Aug 17];40(23):6168\u201395. Available from: https:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2011\/dt\/c0dt01595d","DOI":"10.1039\/c0dt01595d"},{"issue":"2","key":"1325_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00775-015-1318-7","volume":"21","author":"N Wu","year":"2016","unstructured":"Wu N, Kang CS, Sin I, Ren S, Liu D, Ruthengael VC, et al. Promising bifunctional chelators for copper 64-PET imaging: practical 64Cu radiolabeling and high in vitro and in vivo complex stability. J Biol Inorg Chem. 2016;21(2):177\u201384.","journal-title":"J Biol Inorg Chem"},{"issue":"7","key":"1325_CR60","first-page":"1155","volume":"38","author":"Y Fujibayashi","year":"1997","unstructured":"Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38(7):1155\u201360.","journal-title":"J Nucl Med"},{"issue":"11","key":"1325_CR61","first-page":"1958","volume":"39","author":"TR Wallhaus","year":"1998","unstructured":"Wallhaus TR, Lacy J, Whang J, Green MA, Nickles RJ, Stone CK. Human biodistribution and dosimetry of the PET perfusion agent Copper-62-PTSM. J Nucl Med. 1998;39(11):1958\u201364.","journal-title":"J Nucl Med"},{"issue":"1","key":"1325_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1874471011666171211161851","volume":"11","author":"GA Follacchio","year":"2017","unstructured":"Follacchio GA, De Feo MS, De Vincentis G, Monteleone F, Liberatore M. Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm. 2017;11(1):22\u201333.","journal-title":"Curr Radiopharm"},{"issue":"12","key":"1325_CR63","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1007\/s00259-022-05887-6","volume":"49","author":"F Xie","year":"2022","unstructured":"Xie F, Wei W. [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation. Eur J Nucl Med Mol Imaging. 2022;49(12):3964\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"42","key":"1325_CR64","doi-asserted-by":"publisher","first-page":"14612","DOI":"10.1039\/C7DT02008B","volume":"46","author":"OC Brown","year":"2017","unstructured":"Brown OC, Bagu\u00f1a Torres J, Holt KB, Blower PJ, Went MJ. Copper complexes with dissymmetrically substituted bis(thiosemicarbazone) ligands as a basis for PET radiopharmaceuticals: control of redox potential and lipophilicity. Dalton Trans. 2017;46(42):14612\u201330.","journal-title":"Dalton Trans"},{"issue":"9","key":"1325_CR65","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/jlcr.3590","volume":"61","author":"E Boros","year":"2018","unstructured":"Boros E, Holland JP. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. J Labelled Comp Radiopharm. 2018;61(9):652\u201371.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"8","key":"1325_CR66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.nucmedbio.2012.05.009","volume":"39","author":"RA De Silva","year":"2012","unstructured":"De Silva RA, Jain S, Lears KA, Chong HS, Kang CS, Sun X, et al. Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development. Nucl Med Biol. 2012;39(8):1099\u2013104.","journal-title":"Nucl Med Biol"},{"issue":"6","key":"1325_CR67","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1021\/acs.inorgchem.7b02929","volume":"57","author":"V Kub\u00ed\u010dek","year":"2018","unstructured":"Kub\u00ed\u010dek V, B\u00f6hmov\u00e1 Z, \u0160ev\u010d\u00edkov\u00e1 R, Van\u011bk J, Lubal P, Pol\u00e1kov\u00e1 Z, et al. NOTA complexes with Copper(II) and divalent metal ions: kinetic and thermodynamic studies. Inorg Chem. 2018;57(6):3061\u201372.","journal-title":"Inorg Chem"},{"issue":"3","key":"1325_CR68","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1021\/acs.jmedchem.4c02885","volume":"68","author":"P Kr\u0119cisz","year":"2025","unstructured":"Kr\u0119cisz P, Stefa\u0144ska K, Studzi\u0144ski J, Pitucha M, Czylkowska A, Szyma\u0144ski P. Radiocopper in radiopharmacy and medical use: current status and perspective. J Med Chem. 2025;68(3):2356\u201376.","journal-title":"J Med Chem"},{"issue":"2","key":"1325_CR69","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1021\/acs.chemrev.8b00281","volume":"119","author":"E Boros","year":"2019","unstructured":"Boros E, Packard AB. Radioactive transition metals for imaging and therapy. Chem Rev. 2019;119(2):870\u2013901.","journal-title":"Chem Rev"},{"issue":"50","key":"1325_CR70","doi-asserted-by":"publisher","first-page":"20621","DOI":"10.1021\/acs.inorgchem.3c00621","volume":"62","author":"M Tosato","year":"2023","unstructured":"Tosato M, Franchi S, Isse AA, Del Vecchio A, Zanoni G, Alker A, et al. Is smaller better? Cu2+\/Cu\u2009+\u2009coordination chemistry and Copper-64 radiochemical investigation of a 1,4,7-triazacyclononane-based sulfur-rich chelator. Inorg Chem. 2023;62(50):20621\u201333.","journal-title":"Inorg Chem"},{"issue":"1","key":"1325_CR71","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/C3CS60304K","volume":"43","author":"EW Price","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43(1):260\u201390.","journal-title":"Chem Soc Rev"},{"issue":"11","key":"1325_CR72","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.jinorgbio.2004.06.009","volume":"98","author":"SV Smith","year":"2004","unstructured":"Smith SV. Molecular imaging with copper-64. J Inorg Biochem. 2004;98(11):1874\u2013901.","journal-title":"J Inorg Biochem"},{"key":"1325_CR73","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ica.2012.07.012","volume":"393","author":"V Maheshwari","year":"2012","unstructured":"Maheshwari V, Dearling JLJ, Treves ST, Packard AB. Measurement of the rate of copper(II) exchange for 64Cu complexes of bifunctional chelators. Inorg Chim Acta. 2012;393:318\u201323.","journal-title":"Inorg Chim Acta"},{"issue":"6","key":"1325_CR74","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10534-012-9578-y","volume":"25","author":"P Szyma\u0144ski","year":"2012","unstructured":"Szyma\u0144ski P, Fraczek T, Markowicz M, Mikiciuk-Olasik E. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012;25(6):1089\u2013112.","journal-title":"Biometals"},{"issue":"6","key":"1325_CR75","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1021\/jm030383m","volume":"47","author":"CA Boswell","year":"2004","unstructured":"Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of Copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47(6):1465\u201374.","journal-title":"J Med Chem"},{"issue":"6","key":"1325_CR76","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.crci.2013.02.013","volume":"16","author":"JD Silversides","year":"2013","unstructured":"Silversides JD, Burke BP, Archibald SJ. Rapid synthesis of cross-bridged cyclam chelators for copper(II) complex formation. CR Chim. 2013;16(6):524\u201330.","journal-title":"CR Chim"},{"issue":"2","key":"1325_CR77","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.nucmedbio.2012.10.010","volume":"40","author":"M Jiang","year":"2013","unstructured":"Jiang M, Ferdani R, Shokeen M, Anderson CJ. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Nucl Med Biol. 2013;40(2):245\u201351.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"1325_CR78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1039\/C3CC45928D","volume":"50","author":"D Zeng","year":"2014","unstructured":"Zeng D, Ouyang Q, Cai Z, Xie XQ, Anderson CJ. New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides. Chem Commun. 2014;50(1):43\u20135.","journal-title":"Chem Commun"},{"issue":"3","key":"1325_CR79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11307-015-0908-7","volume":"18","author":"JR Nedrow","year":"2016","unstructured":"Nedrow JR, Latoche JD, Day KE, Modi J, Ganguly T, Zeng D, et al. Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET\/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer. Mol Imaging Biol. 2016;18(3):402\u201310.","journal-title":"Mol Imaging Biol"},{"issue":"9","key":"1325_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092244","volume":"13","author":"A Hyv\u00e4kk\u00e4","year":"2021","unstructured":"Hyv\u00e4kk\u00e4 A, Virtanen V, Kemppainen J, Gr\u00f6nroos TJ, Minn H, Sundvall M. More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and beyond. Cancers (Basel). 2021;13(9):2244.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1325_CR81","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263159","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62(11):1489\u201391.","journal-title":"J Nucl Med"},{"issue":"4","key":"1325_CR82","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/JU.0000000000002457","volume":"207","author":"D Kuppermann","year":"2022","unstructured":"Kuppermann D, Calais J, Marks LS. Imaging prostate cancer: clinical utility of prostate-specific membrane antigen. J Urol. 2022;207(4):769\u201378.","journal-title":"J Urol"},{"key":"1325_CR83","doi-asserted-by":"crossref","unstructured":"Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003;170(6 II).","DOI":"10.1097\/01.ju.0000095151.97404.7c"},{"issue":"13","key":"1325_CR84","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/pros.20367","volume":"66","author":"U Els\u00e4sser-Beile","year":"2006","unstructured":"Els\u00e4sser-Beile U, Wolf P, Gierschner D, B\u00fchler P, Schultze-Seemann WG, Wetterauer U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006;66(13):1359\u201370.","journal-title":"Prostate"},{"issue":"4","key":"1325_CR85","doi-asserted-by":"publisher","first-page":"606","DOI":"10.2967\/jnumed.108.058487","volume":"50","author":"U Els\u00e4sser-Beile","year":"2009","unstructured":"Els\u00e4sser-Beile U, Reischl G, Wiehr S, B\u00fchler P, Wolf P, Alt K, et al. Pet imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50(4):606\u201311.","journal-title":"J Nucl Med"},{"issue":"13","key":"1325_CR86","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/pros.21176","volume":"70","author":"K Alt","year":"2010","unstructured":"Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, et al. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate. 2010;70(13):1413\u201321.","journal-title":"Prostate"},{"issue":"1","key":"1325_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2967\/jnumed.116.178780","volume":"58","author":"JW D\u2019Souza","year":"2017","unstructured":"D\u2019Souza JW, Hensley H, Doss M, Beigarten C, Torgov M, Olafsen T, et al. Cerenkov luminescence imaging as a modality to evaluate antibody-based PET radiotracers. J Nucl Med. 2017;58(1):175\u201380.","journal-title":"J Nucl Med"},{"key":"1325_CR88","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.apradiso.2018.09.006","volume":"143","author":"FC Maier","year":"2019","unstructured":"Maier FC, Wild AM, Kirchen N, Holm F, Fuchs K, Schwenck J, et al. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA\u2009+\u2009tumors in mice using 64Cu-radiolabeled monoclonal antibodies. Appl Radiat Isot. 2019;143:149\u201355.","journal-title":"Appl Radiat Isot"},{"key":"1325_CR89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.nucmedbio.2017.01.004","volume":"47","author":"P Wong","year":"2017","unstructured":"Wong P, Li L, Chea J, Delgado MK, Crow D, Poku E, et al. PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): enhanced tumor targeting over anti-PSMA ScFv or untargeted LNPs. Nucl Med Biol. 2017;47:62\u20138.","journal-title":"Nucl Med Biol"},{"issue":"7","key":"1325_CR90","first-page":"247","volume":"32","author":"P Wong","year":"2017","unstructured":"Wong P, Li L, Chea J, Delgado MK, Poku E, Szpikowska B, et al. Synthesis, positron emission tomography imaging, and therapy of Diabody targeted drug lipid nanoparticles in a prostate cancer murine model. Cancer Biother Radiopharm. 2017;32(7):247\u201357.","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"1325_CR91","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1021\/acs.molpharmaceut.4c01193","volume":"22","author":"NL Fletcher","year":"2025","unstructured":"Fletcher NL, Houston ZH, Chandler PG, Yan E, Holgate R, Wheatcroft M, et al. Development of a novel engineered antibody format for PSMA-targeted radionuclide therapy. Mol Pharm. 2025;22(7):3666\u20133678. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01193","journal-title":"Mol Pharm"},{"issue":"6","key":"1325_CR92","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1021\/acs.molpharmaceut.9b00181","volume":"16","author":"WG Lesniak","year":"2019","unstructured":"Lesniak WG, Boinapally S, Banerjee SR, Behnam Azad B, Foss CA, Shen C, et al. Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer. Mol Pharm. 2019;16(6):2590\u2013604.","journal-title":"Mol Pharm"},{"key":"1325_CR93","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.2147\/IJN.S454128","volume":"19","author":"WG Lesniak","year":"2024","unstructured":"Lesniak WG, Boinapally S, Lofland G, Jiang Z, Foss CA, Azad BB, et al. Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug conjugates for treatment of prostate cancer: preclinical evaluation. Int J Nanomed. 2024;19:4995\u20135010.","journal-title":"Int J Nanomed"},{"issue":"8","key":"1325_CR94","first-page":"277","volume":"31","author":"B Grubm\u00fcller","year":"2016","unstructured":"Grubm\u00fcller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. 64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm. 2016;31(8):277\u201386.","journal-title":"Cancer Biother Radiopharm"},{"key":"1325_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.urology.2017.04.019","volume":"106","author":"F Cantiello","year":"2017","unstructured":"Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, et al. Diagnostic accuracy of 64Copper prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience. Urology. 2017;106:139\u201345.","journal-title":"Urology"},{"issue":"5","key":"1325_CR96","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clgc.2018.05.014","volume":"16","author":"F Cantiello","year":"2018","unstructured":"Cantiello F, Crocerossa F, Russo GI, Gangemi V, Ferro M, Vartolomei MD, et al. Comparison between 64Cu-PSMA-617 PET\/CT and 18F-choline PET\/CT imaging in early diagnosis of prostate cancer biochemical recurrence. Clin Genitourin Cancer. 2018;16(5):385\u201391.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1325_CR97","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/RLU.0000000000002786","volume":"45","author":"A Annovazzi","year":"2020","unstructured":"Annovazzi A, Faiella A, Pescarmona E, Sanguineti G, Sciuto R. Asymptomatic metastasis to thyroid cartilage detected by 18F-choline and 64Cu-PSMA PET\/CT as a single site of disease relapse in a patient with castration-resistant prostate carcinoma. Clin Nucl Med. 2020;45(3):214\u20136.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1325_CR98","first-page":"180","volume":"9","author":"C Farhan","year":"2021","unstructured":"Farhan C, Mirzaei S. Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu\u2013PSMA PET\/CT) in a patient with prostate cancer. Asia Ocean J Nucl Med Biol. 2021;9(2):180\u20132.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"3","key":"1325_CR99","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/1874471012666190515090755","volume":"12","author":"F Calabria","year":"2019","unstructured":"Calabria F, Pichler R, Leporace M, Wolfsgruber J, Coscarelli P, Dunzinger A, et al. 68Ga\/64Cu PSMA Bio-Distribution in prostate cancer patients: potential pitfalls for different tracers. Curr Radiopharm. 2019;12(3):238\u201346.","journal-title":"Curr Radiopharm"},{"issue":"8","key":"1325_CR100","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/jlcr.3745","volume":"62","author":"S Hober\u00fcck","year":"2019","unstructured":"Hober\u00fcck S, Wunderlich G, Michler E, H\u00f6lscher T, Walther M, Seppelt D, et al. Dual-time-point 64Cu-PSMA-617-PET\/CT in patients suffering from prostate cancer. J Labelled Comp Radiopharm. 2019;62(8):523\u201332.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"2","key":"1325_CR101","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1097\/RLU.0000000000003758","volume":"47","author":"DR Cardoza-Ochoa","year":"2022","unstructured":"Cardoza-Ochoa DR, Rivera-Bravo B. A comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 patients with metastatic prostate cancer. Clin Nucl Med. 2022;47(2):E120\u20132.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"1325_CR102","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cbic.201900632","volume":"21","author":"ML Lepage","year":"2020","unstructured":"Lepage ML, Kuo HT, Roxin \u00c1, Huh S, Zhang Z, Kandasamy R, et al. Toward 18F-labeled theranostics: a single agent that can be labeled with 18F, 64Cu, or 177Lu. Chembiochem. 2020;21(7):943\u20137.","journal-title":"Chembiochem"},{"issue":"5","key":"1325_CR103","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.3390\/curroncol28050353","volume":"28","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Lipp R, Zandieh S, Leisser A. Single-center comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET\u2013CT for imaging prostate cancer. Curr Oncol. 2021;28(5):4167\u201373.","journal-title":"Curr Oncol"},{"issue":"6","key":"1325_CR104","first-page":"417","volume":"37","author":"CH Lee","year":"2022","unstructured":"Lee CH, Lim I, Woo SK, Kim K, Il, Lee KC, Song K, et al. The feasibility of 64Cu-PSMA I&T PET for prostate cancer. Cancer Biother Radiopharm. 2022;37(6):417\u201323.","journal-title":"Cancer Biother Radiopharm"},{"key":"1325_CR105","doi-asserted-by":"crossref","unstructured":"Nelson BJB, Leier S, Wilson J, Wuest M, Doupe J, Andersson JD et al. 64Cu production via the 68Zn(p,n\u03b1)64Cu nuclear reaction: an untapped, cost-effective and high energy production route. Nucl Med Biol. 2024;128\u20139.","DOI":"10.1016\/j.nucmedbio.2024.108875"},{"issue":"9","key":"1325_CR106","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2967\/jnumed.123.267126","volume":"65","author":"TB Bernabeu","year":"2024","unstructured":"Bernabeu TB, Mansi R, Del Pozzo L, Zanger S, Gaonkar RH, McDougall L, et al. 61Cu-PSMA\u2013targeted PET for prostate cancer: from radiotracer development to first-in-human imaging. J Nucl Med. 2024;65(9):1427\u201334.","journal-title":"J Nucl Med"},{"issue":"4","key":"1325_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040469","volume":"18","author":"D Rodrigues","year":"2025","unstructured":"Rodrigues D, Fonseca AI, do Carmo S, Sereno J, Hrynchak I, Moreira JN, et al. Is copper-61 the new Gallium-68? Automation and preclinical proof-of-concept of 61Cu-based radiopharmaceuticals for prostate cancer imaging. Pharmaceuticals. 2025;18(4):469.","journal-title":"Pharmaceuticals"},{"key":"1325_CR108","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1021\/acsptsci.4c00685","volume":"8","author":"S Bunda","year":"2025","unstructured":"Bunda S, K\u00e1lm\u00e1n-Szab\u00f3 I, Szikra D, Fekete A, Sz\u00fccs D, Szab\u00f3 JP, et al. In vivo evaluation of Copper-61-labeled Prostate-specific membrane antigen targeting novel radiopharmaceutical: first steps toward clinical implementation. ACS Pharmacol Transl Sci. 2025;8:1580\u201390.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1325_CR109","doi-asserted-by":"publisher","unstructured":"Zhang J, Niu S, Liu Y, Zhang X, Luan X, Liu H, et al. Real-time diagnosis of sampled lesions in targeted biopsy of prostate cancer using a novel tracer [64Cu]Cu-DOTA-PSMA-3Q: a pilot preclinical study. Eur J Nucl Med Mol Imaging. 2024;52(4):1257\u20131270. https:\/\/doi.org\/10.1007\/s00259-024-07000-5","DOI":"10.1007\/s00259-024-07000-5"},{"key":"1325_CR110","doi-asserted-by":"publisher","unstructured":"Liu H, Zhang X, Zhang J, Pan Y, Wen H, Xu X, et al. Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET\/CT imaging. Eur J Nucl Med Mol Imaging. 2025;52(8):2792\u20132803. https:\/\/doi.org\/10.1007\/s00259-025-07131-3","DOI":"10.1007\/s00259-025-07131-3"},{"key":"1325_CR111","doi-asserted-by":"publisher","unstructured":"Chen F, Zhang H, Zhan Y, Huang X, He Z, Ma D, et al. Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET\/CT for prostate cancer detection and its comparison with [18F]FDG imaging. Sci Rep. 2025;15(1):14431. https:\/\/doi.org\/10.1038\/s41598-025-98757-8","DOI":"10.1038\/s41598-025-98757-8"},{"key":"1325_CR112","doi-asserted-by":"crossref","unstructured":"Bartholom\u00e4 M, Rosar F, Burgard C, Maus S, Schreck MV, Ezziddin S. Novel 64Cu-labeled trimeric PSMA ligand unequivocally identifies local recurrence of prostate cancer ambiguously imaged by 18F-DCFPyL PSMA PET\/CT. Clin Nucl Med. 2025.","DOI":"10.1097\/RLU.0000000000006010"},{"key":"1325_CR113","doi-asserted-by":"publisher","unstructured":"Lim J, Guan B, Nham K, Hao G, Sun X, Simanek EE. Tumor uptake of triazine dendrimers decorated with four, sixteen, and sixty-four PSMA-targeted ligands: passive versus active tumor targeting. Biomolecules. 2019;9(9):421. https:\/\/doi.org\/10.3390\/biom9090421","DOI":"10.3390\/biom9090421"},{"issue":"6","key":"1325_CR114","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1021\/jm401921j","volume":"57","author":"SR Banerjee","year":"2014","unstructured":"Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, et al. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;57(6):2657\u201369.","journal-title":"J Med Chem"},{"key":"1325_CR115","doi-asserted-by":"publisher","unstructured":"Gourni E, Canovas C, Goncalves V, Denat F, Meyer PT, Maecke HR. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors. PLoS ONE. 2015;10(12). https:\/\/doi.org\/10.1371\/journal.pone.0145755","DOI":"10.1371\/journal.pone.0145755"},{"key":"1325_CR116","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nucmedbio.2018.03.002","volume":"60","author":"T L\u00e4ppchen","year":"2018","unstructured":"L\u00e4ppchen T, Kiefer Y, Holland JP, Bartholom\u00e4 MD. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector. Nucl Med Biol. 2018;60:45\u201354.","journal-title":"Nucl Med Biol"},{"issue":"12","key":"1325_CR117","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1021\/acs.molpharmaceut.8b00712","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Bene\u0161ov\u00e1 M, Hasler R, Schibli R, Van Der Meulen NP, M\u00fcller C. Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging. Mol Pharm. 2018;15(12):5556\u201364.","journal-title":"Mol Pharm"},{"key":"1325_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13162649","volume":"13","author":"I Lee","year":"2023","unstructured":"Lee I, Kim MH, Lee K, Oh K, Lim H, Ahn JH, et al. Comparison of the effects of DOTA and NOTA chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for prostate cancer. Diagnostics. 2023;13:16.","journal-title":"Diagnostics"},{"key":"1325_CR119","doi-asserted-by":"crossref","unstructured":"Lewis MR, Schaedler AW, Ho K, Van, Golzy M, Mathur A, Pun M et al. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen. Nucl Med Biol. 2024;136\u20137.","DOI":"10.1016\/j.nucmedbio.2024.108938"},{"key":"1325_CR120","doi-asserted-by":"publisher","unstructured":"Milot MC, Benesty OB, Dumulon-Perreault V, Ait-Mohand S, Richard PO, Rousseau \u00c9, et al. 64Cu-DOTHA2-PSMA, a novel PSMA PET radiotracer for prostate cancer with a long imaging time window. Pharmaceuticals. 2022;15(8):996. https:\/\/doi.org\/10.3390\/ph15080996","DOI":"10.3390\/ph15080996"},{"key":"1325_CR121","doi-asserted-by":"publisher","first-page":"1073491","DOI":"10.3389\/fonc.2023.1073491","volume":"13","author":"MC Milot","year":"2023","unstructured":"Milot MC, B\u00e9lissant-Benesty O, Dumulon-Perreault V, Ait-Mohand S, Geha S, Richard PO, et al. Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model. Front Oncol. 2023;13:1073491. https:\/\/doi.org\/10.3389\/fonc.2023.1073491","journal-title":"Front Oncol"},{"issue":"8","key":"1325_CR122","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1021\/mp4000844","volume":"10","author":"G Hao","year":"2013","unstructured":"Hao G, Kumar A, Dobin T, \u00d6z OK, Hsieh JT, Sun X. A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. Mol Pharm. 2013;10(8):2975\u201385.","journal-title":"Mol Pharm"},{"issue":"11","key":"1325_CR123","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1021\/acs.bioconjchem.8b00636","volume":"29","author":"KM Harmatys","year":"2018","unstructured":"Harmatys KM, Overchuk M, Chen J, Ding L, Chen Y, Pomper MG, et al. Tuning pharmacokinetics to improve tumor accumulation of a Prostate-Specific membrane Antigen-Targeted phototheranostic agent. Bioconjug Chem. 2018;29(11):3746\u201356.","journal-title":"Bioconjug Chem"},{"key":"1325_CR124","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12325-018-0711-3","volume":"35","author":"S Sevcenco","year":"2018","unstructured":"Sevcenco S, Klingler HC, Eredics K, Friedl A, Schneeweiss J, Knoll P, et al. Application of Cu-64 NODAGA-PSMA PET in prostate cancer. Adv Ther. 2018;35(6):779\u201384. https:\/\/doi.org\/10.1007\/s12325-018-0711-3","journal-title":"Adv Ther"},{"issue":"1","key":"1325_CR125","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.119.229054","volume":"61","author":"JC dos Santos","year":"2020","unstructured":"dos Santos JC, Beijer B, Bauder-W\u00fcst U, Sch\u00e4fer M, Leotta K, Eder M, et al. Development of novel PSMA ligands for imaging and therapy with copper isotopes. J Nucl Med. 2020;61(1):70\u20139.","journal-title":"J Nucl Med"},{"issue":"13","key":"1325_CR126","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","volume":"48","author":"T Liu","year":"2021","unstructured":"Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, et al. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(13):4508\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"42","key":"1325_CR127","doi-asserted-by":"publisher","first-page":"15133","DOI":"10.1002\/ange.201908964","volume":"131","author":"NA Zia","year":"2019","unstructured":"Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, et al. A bivalent inhibitor of prostate specific membrane antigen radiolabeled with copper-64 with high tumor uptake and retention. Angew Chem. 2019;131(42):15133\u20136.","journal-title":"Angew Chem"},{"issue":"6","key":"1325_CR128","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2967\/jnumed.120.251579","volume":"62","author":"LE McInnes","year":"2021","unstructured":"McInnes LE, Cullinane C, Roselt PD, Jackson S, Blyth BJ, van Dam EM, et al. Therapeutic efficacy of a bivalent inhibitor of Prostate-Specific membrane antigen labeled with 67Cu. J Nucl Med. 2021;62(6):829\u201332.","journal-title":"J Nucl Med"},{"issue":"6","key":"1325_CR129","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","volume":"17","author":"JM Kelly","year":"2020","unstructured":"Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Nikolopoulou A, et al. Preclinical evaluation of a high-affinity sarcophagine-containing PSMA ligand for 64Cu\/67Cu-based theranostics in prostate cancer. Mol Pharm. 2020;17(6):1954\u201362.","journal-title":"Mol Pharm"},{"key":"1325_CR130","unstructured":"PROPELLER Trial Results \u2013 SAR-bisPSMA, Safe. Well Tolerated and Efficacious in the Detection of Prostate Cancer [Internet]. 2023 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/propeller_results\/"},{"key":"1325_CR131","unstructured":"Registrational Phase III, CLARIFY trial in prostate cancer commences [Internet]. 2023 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/clarifyphase3\/"},{"key":"1325_CR132","unstructured":"Initial COBRA. results: Clarity\u2019s SAR-bisPSMA is safe and highly effective in detecting tumours in prostate cancer patients. Phase 3 planning underway. 2024 Feb 15 [cited 2025 May 18]; Available from: https:\/\/www.claritypharmaceuticals.com\/news\/cobra_results\/"},{"key":"1325_CR133","unstructured":"Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer [Internet]. 2024 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/fda_amplify\/"},{"key":"1325_CR134","unstructured":"SECuRE trial advances. No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort [Internet]. 2024 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/c4_update\/"},{"key":"1325_CR135","unstructured":"SECuRE trial update. 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. [Internet]. 2025 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/secure-update\/"},{"key":"1325_CR136","unstructured":"Clarity Update. Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq [Internet]. 2024 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/complete_response\/"},{"key":"1325_CR137","unstructured":"SECuRE trial update. First patient treated in the Phase II Cohort Expansion [Internet]. 2025 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/secure-fp-phase2\/"},{"key":"1325_CR138","unstructured":"St Vincent\u2019. s Hospital to conduct head-to-head trial with Clarity\u2019s SAR-bisPSMA diagnostic product [Internet]. 2024 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/co-psma\/"},{"key":"1325_CR139","unstructured":"First 2 participants dosed with Cu. -64 SAR-bisPSMA in Co-PSMA trial [Internet]. 2024 [cited 2025 May 18]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/co-psma-fp\/"},{"issue":"9","key":"1325_CR140","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.124.267881","volume":"65","author":"S Li","year":"2024","unstructured":"Li S, Nguyen A, Counter W, John NC, De Leon J, Hruby G, et al. Utility of 64Cu-sarcophagine-bombesin PET\/CT in men with biochemically recurrent prostate cancer and negative or equivocal findings on 68Ga-PSMA-11 PET\/CT. J Nucl Med. 2024;65(9):1371\u20135.","journal-title":"J Nucl Med"},{"issue":"4","key":"1325_CR141","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/bc034018l","volume":"14","author":"BE Rogers","year":"2003","unstructured":"Rogers BE, Bigott HM, McCarthy DW, Manna D, Della, Kim J, Sharp TL, et al. MicroPET imaging of a Gastrin-Releasing peptide Receptor-Positive tumor in a mouse model of human prostate cancer using a 64Cu-Labeled Bombesin analogue. Bioconjug Chem. 2003;14(4):756\u201363.","journal-title":"Bioconjug Chem"},{"issue":"8","key":"1325_CR142","first-page":"1390","volume":"45","author":"X Chen","year":"2004","unstructured":"Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]Bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45(8):1390\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"1325_CR143","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.nucmedbio.2005.12.011","volume":"33","author":"YS Yang","year":"2006","unstructured":"Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled Bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol. 2006;33(3):371\u201380.","journal-title":"Nucl Med Biol"},{"issue":"3","key":"1325_CR144","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/bc060281l","volume":"18","author":"GB Biddlecombe","year":"2007","unstructured":"Biddlecombe GB, Rogers BE, De Visser M, Parry JJ, De Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1\u201314). Bioconjug Chem. 2007;18(3):724\u201330.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"1325_CR145","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1021\/bc0603788","volume":"18","author":"JJ Parry","year":"2007","unstructured":"Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7\u201314) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18(4):1110\u20137.","journal-title":"Bioconjug Chem"},{"issue":"8","key":"1325_CR146","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2967\/jnumed.107.039487","volume":"48","author":"JC Garrison","year":"2007","unstructured":"Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET\/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48(8):1327\u201337.","journal-title":"J Nucl Med"},{"issue":"12","key":"1325_CR147","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2967\/jnumed.111.094375","volume":"52","author":"K Abiraj","year":"2011","unstructured":"Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52(12):1970\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"1325_CR148","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7150\/thno.7324","volume":"4","author":"G Wieser","year":"2014","unstructured":"Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a Gastrin releasing peptide receptor antagonist - from mice to men. Theranostics. 2014;4(4):412\u20139.","journal-title":"Theranostics"},{"key":"1325_CR149","doi-asserted-by":"crossref","unstructured":"Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC et al. [64Cu-NOTA-8-Aoc-BBN(7\u201314)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A [Internet]. 2007;104(30):12462\u20137. Available from: www.pnas.orgcgidoi10.1073pnas.0705347104.","DOI":"10.1073\/pnas.0705347104"},{"issue":"7","key":"1325_CR150","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.nucmedbio.2010.04.016","volume":"37","author":"SR Lane","year":"2010","unstructured":"Lane SR, Nanda P, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, et al. Optimization, biological evaluation and micropet imaging of copper-64-labeled Bombesin agonists, [64Cu-NO2A-(X)-BBN(7\u201314)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol. 2010;37(7):751\u201361.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"1325_CR151","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nucmedbio.2011.12.004","volume":"39","author":"JM Craft","year":"2012","unstructured":"Craft JM, De Silva RA, Lears KA, Andrews R, Liang K, Achilefu S, et al. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Nucl Med Biol. 2012;39(5):609\u201316.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"1325_CR152","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nucmedbio.2011.10.009","volume":"39","author":"PK Nanda","year":"2012","unstructured":"Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol. 2012;39(4):461\u201371.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"1325_CR153","first-page":"583","volume":"26","author":"PK Nanda","year":"2012","unstructured":"Nanda PK, Wienhoff BE, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, et al. Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. Antagonist ligands. Vivo (Brooklyn). 2012;26(4):583\u201392.","journal-title":"Vivo (Brooklyn)"},{"issue":"12","key":"1325_CR154","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2967\/jnumed.113.121533","volume":"54","author":"Y Liu","year":"2013","unstructured":"Liu Y, Hu X, Liu H, Bu L, Ma X, Cheng K, et al. A comparative study of radiolabeled Bombesin analogs for the PET imaging of prostate cancer. J Nucl Med. 2013;54(12):2132\u20138.","journal-title":"J Nucl Med"},{"issue":"24","key":"1325_CR155","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/molecules25245993","volume":"25","author":"C Baun","year":"2020","unstructured":"Baun C, Mitran B, Rinne SS, Dam JH, Olsen BB, Tolmachev V, et al. Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer. Molecules. 2020;25(24):5993. https:\/\/doi.org\/10.3390\/molecules25245993","journal-title":"Molecules"},{"issue":"10","key":"1325_CR156","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.114.141242","volume":"55","author":"E Gourni","year":"2014","unstructured":"Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, et al. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. J Nucl Med. 2014;55(10):1719\u201325.","journal-title":"J Nucl Med"},{"issue":"7","key":"1325_CR157","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1021\/acs.bioconjchem.0c00656","volume":"32","author":"G Makris","year":"2021","unstructured":"Makris G, Shegani A, Kankanamalage PHA, Kuchuk M, Bandari RP, Smith CJ, et al. Preclinical evaluation of novel 64Cu-labeled gastrin-releasing peptide receptor bioconjugates for PET imaging of prostate cancer. Bioconjug Chem. 2021;32(7):1290\u20137.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"1325_CR158","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3892\/ijo.2015.2832","volume":"46","author":"MH Kim","year":"2015","unstructured":"Kim MH, Park JA, Woo SK, Lee KC, An G, Il, Kim BS, et al. Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model. Int J Oncol. 2015;46(3):1159\u201368.","journal-title":"Int J Oncol"},{"issue":"4","key":"1325_CR159","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jlcr.3491","volume":"60","author":"N Mansour","year":"2017","unstructured":"Mansour N, Dumulon-Perreault V, Ait-Mohand S, Paquette M, Lecomte R, Gu\u00e9rin B. Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [64Cu]Cu\/NOTA peptide-based gastrin-releasing peptide receptors antagonists. J Labelled Comp Radiopharm. 2017;60(4):200\u201312.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"3","key":"1325_CR160","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2967\/jnumed.110.082826","volume":"52","author":"KA Lears","year":"2011","unstructured":"Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52(3):470\u20137.","journal-title":"J Nucl Med"},{"issue":"8","key":"1325_CR161","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1021\/mp500671j","volume":"12","author":"E Gourni","year":"2015","unstructured":"Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, et al. Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Mol Pharm. 2015;12(8):2781\u201390.","journal-title":"Mol Pharm"},{"key":"1325_CR162","unstructured":"Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial [Internet]. 2023 [cited 2025 Jun 12]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/sabre_closed\/"},{"issue":"6","key":"1325_CR163","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/ph15060728","volume":"15","author":"TT Huynh","year":"2022","unstructured":"Huynh TT, van Dam EM, Sreekumar S, Mpoy C, Blyth BJ, Muntz F, et al. Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals. 2022;15(6):728. https:\/\/doi.org\/10.3390\/ph15060728","journal-title":"Pharmaceuticals"},{"key":"1325_CR164","unstructured":"Clarity commences COMBAT theranostic prostate cancer trial in the US [Internet]. 2023 [cited 2025 Jun 12]. Available from: https:\/\/www.claritypharmaceuticals.com\/news\/combat_commences-us\/"},{"issue":"2","key":"1325_CR165","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/bc800461e","volume":"20","author":"S Juran","year":"2009","unstructured":"Juran S, Walther M, Stephan H, Bergmann R, Steinbach J, Kraus W, et al. Hexadentate bispidine derivatives as versatile bifunctional chelate agents for copper(II) radioisotopes. Bioconjug Chem. 2009;20(2):347\u201359.","journal-title":"Bioconjug Chem"},{"key":"1325_CR166","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ejmech.2013.10.013","volume":"70","author":"R Bergmann","year":"2013","unstructured":"Bergmann R, Ruffani A, Graham B, Spiccia L, Steinbach J, Pietzsch J, et al. Synthesis and radiopharmacological evaluation of 64Cu-labeled Bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator. Eur J Med Chem. 2013;70:434\u201346.","journal-title":"Eur J Med Chem"},{"key":"1325_CR167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2017.10.006","volume":"56","author":"N Mansour","year":"2018","unstructured":"Mansour N, Paquette M, Ait-Mohand S, Dumulon-Perreault V, Gu\u00e9rin B. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [64Cu]-DOTHA2-PEG-RM26. Nucl Med Biol. 2018;56:31\u20138.","journal-title":"Nucl Med Biol"},{"issue":"14","key":"1325_CR168","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2217\/nnm-2018-0062","volume":"13","author":"H Cai","year":"2018","unstructured":"Cai H, Xie F, Mulgaonkar A, Chen L, Sun X, Hsieh JT, et al. Bombesin functionalized 64Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine. 2018;13(14):1695\u20131705. https:\/\/doi.org\/10.2217\/nnm-2018-0062","journal-title":"Nanomedicine"},{"key":"1325_CR169","doi-asserted-by":"crossref","unstructured":"Fournier P, Dumulon-Perreault V, Ait-Mohand S, Langlois R, B\u00e9nard F, Lecomte R et al. Comparative study of 64Cu\/NOTA-[D-Tyr6,bAla11,Thi13,Nle14]BBN(6\u201314) monomer and dimers for prostate cancer PET imaging. EJNMMI Res [Internet]. 2012;2(8). Available from: http:\/\/www.ejnmmires.com\/content\/2\/1\/8","DOI":"10.1186\/2191-219X-2-8"},{"issue":"4","key":"1325_CR170","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.nucmedbio.2014.01.001","volume":"41","author":"RP Bandari","year":"2014","unstructured":"Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, et al. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7\u201314)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr\/PSMA) of prostate cancer. Nucl Med Biol. 2014;41(4):355\u201363.","journal-title":"Nucl Med Biol"},{"issue":"1\u20132","key":"1325_CR171","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijpharm.2018.05.014","volume":"545","author":"K Matsumura","year":"2018","unstructured":"Matsumura K, Zouda M, Wada Y, Yamashita F, Hashida M, Watanabe Y, et al. Urokinase injection-triggered clearance enhancement of a 4-arm PEG-conjugated 64Cu-bombesin analog tetramer: a novel approach for the improvement of PET imaging contrast. Int J Pharm. 2018;545(1\u20132):206\u201314.","journal-title":"Int J Pharm"},{"issue":"19","key":"1325_CR172","doi-asserted-by":"publisher","first-page":"9673","DOI":"10.1158\/0008-5472.CAN-06-1480","volume":"66","author":"W Cai","year":"2006","unstructured":"Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin\u2122, a humanized monoclonal antibody against integrin \u03b1v\u03b23. Cancer Res. 2006;66(19):9673\u201381.","journal-title":"Cancer Res"},{"issue":"7","key":"1325_CR173","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.2967\/jnumed.108.061739","volume":"50","author":"Z Liu","year":"2009","unstructured":"Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50(7):1168\u201377.","journal-title":"J Nucl Med"},{"issue":"3","key":"1325_CR174","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nucmedbio.2011.10.004","volume":"39","author":"AB Jackson","year":"2012","unstructured":"Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, et al. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7\u201314)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol. 2012;39(3):377\u201387.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"1325_CR175","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nucmedbio.2013.11.006","volume":"41","author":"K Durkan","year":"2014","unstructured":"Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, et al. A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] \u03b1v\u03b23\/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol. 2014;41(2):133\u20139.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"1325_CR176","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.8b00113","volume":"29","author":"E Lucente","year":"2018","unstructured":"Lucente E, Liu H, Liu Y, Hu X, Lacivita E, Leopoldo M, et al. Novel 64Cu labeled RGD2-BBN heterotrimers for PET imaging of prostate cancer. Bioconjug Chem. 2018;29(5):1595\u2013604.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"1325_CR177","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2310\/7290.2012.00038","volume":"12","author":"J Yuan","year":"2013","unstructured":"Yuan J, Zhang H, Kaur H, Oupicky D, Peng F. Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA-64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron emission tomography. Mol Imaging. 2013;12(3):203\u201312. https:\/\/doi.org\/10.2310\/7290.2012.00038","journal-title":"Mol Imaging"},{"issue":"10\u201312","key":"1325_CR178","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00726-019-02794-3","volume":"51","author":"H Jadvar","year":"2019","unstructured":"Jadvar H, Chen K, Park R, Yap LP, Vorobyova I, Swenson S, et al. Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer. Amino Acids. 2019;51(10\u201312):1569\u201375.","journal-title":"Amino Acids"},{"issue":"30","key":"1325_CR179","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1016\/j.biomaterials.2014.06.059","volume":"35","author":"H Hu","year":"2014","unstructured":"Hu H, Li D, Liu S, Wang M, Moats R, Conti PS, et al. Integrin \u03b12\u03b21 targeted GdVO4:Eu ultrathin nanosheet for multimodal PET\/MR imaging. Biomaterials. 2014;35(30):8649\u201358.","journal-title":"Biomaterials"},{"issue":"2","key":"1325_CR180","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2967\/jnumed.110.081943","volume":"52","author":"C Xiong","year":"2011","unstructured":"Xiong C, Huang M, Zhang R, Song S, Lu W, Flores L, et al. In vivo small-animal PET\/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med. 2011;52(2):241\u20138.","journal-title":"J Nucl Med"},{"key":"1325_CR181","doi-asserted-by":"publisher","unstructured":"Ullman C, Mathonet P, Oleksy A, Diamandakis A, Tomei L, Demartis A, et al. High affinity binders to EphA2 isolated from abdurin scaffold libraries; characterization, binding and tumor targeting. PLoS ONE. 2015;10(8). https:\/\/doi.org\/10.1371\/journal.pone.0135278","DOI":"10.1371\/journal.pone.0135278"},{"issue":"14","key":"1325_CR182","doi-asserted-by":"publisher","first-page":"127262","DOI":"10.1016\/j.bmcl.2020.127262","volume":"30","author":"A Pyo","year":"2020","unstructured":"Pyo A, You SH, Sik Kim H, Young Kim J, Min JJ, Kim DY, et al. Production of 64Cu-labeled monobody for imaging of human EphA2-expressing tumors. Bioorg Med Chem Lett. 2020;30(14):127262. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127262","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"1325_CR183","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2967\/jnumed.107.043703","volume":"49","author":"K Zhang","year":"2008","unstructured":"Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med. 2008;49(1):112\u201321.","journal-title":"J Nucl Med"},{"key":"1325_CR184","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.urology.2015.10.012","volume":"88","author":"S Tripathi","year":"2016","unstructured":"Tripathi S, Trabulsi EJ, Gomella L, Kim S, McCue P, Intenzo C, et al. VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: preliminary evaluation in man. Urology. 2016;88:111\u20138.","journal-title":"Urology"},{"key":"1325_CR185","doi-asserted-by":"publisher","first-page":"153601211771136","DOI":"10.1177\/1536012117711369","volume":"16","author":"H Deng","year":"2017","unstructured":"Deng H, Wang H, Zhang H, Wang M, Giglio B, Ma X, et al. Imaging neurotensin receptor in prostate cancer with 64Cu-labeled neurotensin analogs. Mol Imaging. 2017;16:1536012117711369. https:\/\/doi.org\/10.1177\/1536012117711369","journal-title":"Mol Imaging"},{"issue":"1","key":"1325_CR186","first-page":"65","volume":"1","author":"G Hao","year":"2011","unstructured":"Hao G, Hajibeigi A, Le\u00f3n-Rodr\u00edguez LM, De, \u00d6z OK, Sun X. Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging. 2011;1(1):65\u201375.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"1325_CR187","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/bc300473x","volume":"24","author":"ED Pressly","year":"2013","unstructured":"Pressly ED, Pierce RA, Connal LA, Hawker CJ, Liu Y. Nanoparticle PET\/CT imaging of natriuretic peptide clearance receptor in prostate cancer. Bioconjug Chem. 2013;24(2):196\u2013204.","journal-title":"Bioconjug Chem"},{"issue":"9","key":"1325_CR188","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2967\/jnumed.112.106302","volume":"53","author":"MA Hall","year":"2012","unstructured":"Hall MA, Pinkston KL, Wilganowski N, Robinson H, Ghosh P, Azhdarinia A, et al. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET\/CT and NIRF. J Nucl Med. 2012;53(9):1427\u201337.","journal-title":"J Nucl Med"},{"issue":"8","key":"1325_CR189","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2014.07.010","volume":"16","author":"F Couture","year":"2014","unstructured":"Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D\u2019Anjou F, Day R, et al. PACE4-based molecular targeting of prostate cancer using an engineered 64Cu-radiolabeled peptide inhibitor. Neoplasia. 2014;16(8):634\u201343.","journal-title":"Neoplasia"},{"issue":"9","key":"1325_CR190","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/ph15091109","volume":"15","author":"JH Park","year":"2022","unstructured":"Park JH, Zhang X, Ha H, Kim JY, Choi JY, Lee KH, et al. A high-affinity 64Cu-labeled ligand for PET imaging of hepsin: design, synthesis, and characterization. Pharmaceuticals. 2022;15(9):1109. https:\/\/doi.org\/10.3390\/ph15091109","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1325_CR191","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1021\/acsomega.8b02729","volume":"4","author":"Z Han","year":"2019","unstructured":"Han Z, Sergeeva O, Roelle S, Cheng H, Gao S, Li Y, et al. Preparation and evaluation of ZD2 peptide 64Cu-DOTA conjugate as a positron emission tomography probe for detection and characterization of prostate cancer. ACS Omega. 2019;4(1):1185\u201390.","journal-title":"ACS Omega"},{"key":"1325_CR192","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1007\/s00259-020-04721-1","volume":"47","author":"CJ Konopka","year":"2020","unstructured":"Konopka CJ, Wo\u017aniak M, Hedhli J, Siekierzycka A, Skokowski J, P\u0119ksa R, et al. Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:2562\u201376. https:\/\/doi.org\/10.1007\/s00259-020-04721-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1325_CR193","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1021\/acs.bioconjchem.5b00102","volume":"26","author":"A Kumar","year":"2015","unstructured":"Kumar A, Hao G, Liu L, Ramezani S, Hsieh JT, \u00d6z OK, et al. Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold. Bioconjug Chem. 2015;26(4):782\u20139.","journal-title":"Bioconjug Chem"},{"issue":"19","key":"1325_CR194","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.1021\/acs.jmedchem.8b00932","volume":"61","author":"T David","year":"2018","unstructured":"David T, Hlinov\u00e1 V, Kub\u00ed\u010dek V, Bergmann R, Striese F, Berndt N, et al. Improved conjugation, 64-Cu radiolabeling, in vivo stability, and imaging using nonprotected bifunctional macrocyclic ligands: bis(Phosphinate) cyclam (BPC) chelators. J Med Chem. 2018;61(19):8774\u201396.","journal-title":"J Med Chem"},{"key":"1325_CR195","doi-asserted-by":"publisher","unstructured":"Arndt C, Bergmann R, Striese F, Merkel K, M\u00e1th\u00e9 D, Loureiro LR, et al. Development and functional characterization of a versatile radio-\/immunotheranostic tool for prostate cancer management. Cancers (Basel). 2022;14(8):1996. https:\/\/doi.org\/10.3390\/cancers14081996","DOI":"10.3390\/cancers14081996"},{"key":"1325_CR196","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202400366","author":"M Kubeil","year":"2024","unstructured":"Kubeil M, Neuber C, Starke M, Arndt C, Rodrigues Loureiro L, Hoffmann L, et al. 64Cu tumor labeling with hexadentate picolinic acid-based bispidine immunoconjugates. Chem Eur J. 2024;30(32). https:\/\/doi.org\/10.1002\/chem.202400366","journal-title":"Chem Eur J"},{"issue":"2","key":"1325_CR197","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/mp500766x","volume":"12","author":"H Hong","year":"2015","unstructured":"Hong H, Yan Y, Shi S, Graves SA, Krasteva LK, Nickles RJ, et al. PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging. Mol Pharm. 2015;12(2):403\u201310.","journal-title":"Mol Pharm"},{"issue":"5","key":"1325_CR198","doi-asserted-by":"publisher","first-page":"450","DOI":"10.18632\/oncotarget.27895","volume":"12","author":"R Bergmann","year":"2021","unstructured":"Bergmann R, Chollet C, Els-Heindl S, Ullrich M, Berndt N, Pietzsch J, et al. Development of a Ghrelin receptor inverse agonist for positron emission tomography. Oncotarget [Internet]. 2021;12(5):450\u201374. Available from: www.oncotarget.com.","journal-title":"Oncotarget [Internet]"},{"issue":"12","key":"1325_CR199","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.12956","volume":"5","author":"M Persson","year":"2015","unstructured":"Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, et al. First-in-human uPAR PET: imaging of cancer aggressiveness. Theranostics. 2015;5(12):1303\u201316.","journal-title":"Theranostics"},{"key":"1325_CR200","unstructured":"Curasight announces approval of clinical trial application (CTA). for phase 2 trial with uTRACE[\u00ae] in prostate cancer patients [Internet]. 2024 [cited 2025 Jun 12]. Available from: https:\/\/www.curasight.com\/news\/press-releases\/2024\/curasight-announces-approval-of-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients\/"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01325-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T23:04:24Z","timestamp":1763507064000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01325-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":200,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01325-4","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}